Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Devonian Health GroupTSXV:GSD 39 Net Margin % is -1,096.05% as of Apr. 2026. GuruFocus rates TSXV:GSD with a GF Score™ of 39/100. The stock has 7 warning signs investors should review. Among 944 Biotechnology companies, Devonian Health Group ranks worse than 60.81% on this metric.
Devonian Health Group (TSXV:GSD) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Devonian Health Group Net Margin % Related Terms
Devonian Health Group Net Margin % Historical Data
* Premium members only.
The historical data trend for Devonian Health Group's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:GSD vs VRTX, REGN, RVMD: Net Margin % Comparison
For the Biotechnology subindustry, Devonian Health Group's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Devonian Health Group Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Devonian Health Group's Net Margin % distribution charts can be found below:
* The bar in red indicates where Devonian Health Group's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Devonian Health Group (TSXV:GSD) has a Net Margin % of -1,096.05% as of Apr. 2026. Net margin is the ratio of total net income to net sales. View historical data on Devonian Health Group and its competitors. According to the industry distribution chart, Devonian Health Group ranks #574 out of 944 companies in the Biotechnology industry, placing it in the top 60.8%.
Is Devonian Health Group's Net Margin % too high?
Devonian Health Group's current Net Margin % is -1,096.05%. Based on the distribution chart, Devonian Health Group ranks #574 out of 944 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Devonian Health Group has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Devonian Health Group's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Devonian Health Group ranks #574 out of 944 companies for Net Margin %. This places Devonian Health Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Devonian Health Group and its competitors. Devonian Health Group's current Net Margin % is -1,096.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Devonian Health Group stock overvalued right now?
Devonian Health Group (TSXV:GSD) has a current Net Margin % of -1,096.05%. The current Net Margin % is -1,096.05%. Devonian Health Group's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Devonian Health Group (TSXV:GSD), the current Net Margin % is -1,096.05% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.
39GF Score
Get the complete analysis for TSXV:GSD
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:GSD has been successfully added to your 
